Company Overview and News

 
LBT Innovations attracts $7 mln for pathology lab automation technology

2018-03-06 proactiveinvestors.com.au
LBT Innovations Limited (ASX:LBT) has received commitments totalling circa $7 million via a private placement of shares to institutional and sophisticated investors at $0.15 each.
Upvote Downvote

 
SA-made lab technology set for “busy real-life” testing

2017-09-27 perthnow.com.au
ADELAIDE medical technology company LBT Innovations has installed its advanced laboratory product at St Vincent’s Hospital in Melbourne — the first test of the system in a busy real-life setting.
Upvote Downvote

 
Australian Medical Technology Company WoundVue Prototype To Be Used At

2017-08-08 devicespace
NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Australian medical technology company LBT Innovations Limited (ASX:LBT) has entered a collaboration agreement with Central Adelaide Local Health Network (CALHN) Vascular and Endovascular Services, to use LBT's novel WoundVue prototype device in the clinical trial, "Predicting outcomes in patients with diabetic foot ulcers and effectiveness of interventions to improve outcomes".
Upvote Downvote

 
New leadership for SA medical company

2017-07-20 perthnow.com.au
EXPERIENCED company director Kate Costello will take over as chair of ASX-listed South Australian medical technology firm LBT Innovations at the end of the month, replacing the longstanding Bob Finder.
Upvote Downvote

 
Jobs growth sectors to lead to SA investment boost

2017-05-29 perthnow.com.au
ADELAIDE is fast becoming a magnet for international investment which is being underpinned by four significant growth sectors, says a leading national property analyst.
Upvote Downvote

 
LBT Innovations Ltd gets ready to raise

2016-11-30 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Friday 2nd December 2016, or earlier if an announcement is made to the market.
Upvote Downvote

 
Bendigo Bank's Robert Johanson is battle ready

2016-10-23 theage.com.au
Bendigo and Adelaide Bank chairman Robert Johanson will be on track to clock up more than three decades on the bank's board if he is re-elected at this week's annual meeting. But those pesky proxy advisers, wouldn't you know it, are kicking up a stink. ISS, the bane of many a chairman this annual meeting season, is advising investors to vote against Johanson's re-election, citing his "extremely long tenure" on the board, and his role as a director of Grant Samuel, which has provided advisory services to the bank.
Upvote Downvote

 
Bendigo Bank's Robert Johanson is battle ready

2016-10-23 smh.com.au
Bendigo and Adelaide Bank chairman Robert Johanson will be on track to clock up more than three decades on the bank's board if he is re-elected at this week's annual meeting. But those pesky proxy advisers, wouldn't you know it, are kicking up a stink. ISS, the bane of many a chairman this annual meeting season, is advising investors to vote against Johanson's re-election, citing his "extremely long tenure" on the board, and his role as a director of Grant Samuel, which has provided advisory services to the bank.
Upvote Downvote

 
Catherine has her work cut out at Commonwealth Bank

2016-10-12 theage.com.au
What to do about the problems in life insurance will be just one of items on the lengthy "to-do" list awaiting Catherine Livingstone as she slides into the chairman's position at the Commonwealth Bank at the end of this year.
Upvote Downvote

 
Catherine has her work cut out at Commonwealth Bank

2016-10-12 smh.com.au
What to do about the problems in life insurance will be just one of items on the lengthy "to-do" list awaiting Catherine Livingstone as she slides into the chairman's position at the Commonwealth Bank at the end of this year.
Upvote Downvote

 
LBT Innovations among ASX % Gainers intra-day

2016-10-11 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
US FDA Grants Approval For s APAS

2016-10-10 devicespace
ADELAIDE, Australia, Oct.10, 2016 /PRNewswire/ -- Clever Culture Systems AG (CCS), the Swiss based joint venture between Australian medical technology company LBT  Innovations Limited (ASX:  LBT) and Hettich AG (Switzerland) has received clearance of its 510(k) de novosubmission to the US Food and Drug Administration (FDA) for APAS® as a Class II medical device.
Upvote Downvote

 
US FDA Grants Approval for LBT's APAS®

2016-10-10 prnewswire
ADELAIDE, Australia, Oct.10, 2016 /PRNewswire/ -- Clever Culture Systems AG (CCS), the Swiss based joint venture between Australian medical technology company LBT  Innovations Limited (ASX:  LBT) and Hettich AG (Switzerland) has received clearance of its 510(k) de novosubmission to the US Food and Drug Administration (FDA) for APAS® as a Class II medical device.
Upvote Downvote

 
Appendix 3B

2016-05-09 asx.com.au
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...